Journal
NATURE MEDICINE
Volume 20, Issue 3, Pages 236-237Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3493
Keywords
-
Funding
- NIAID NIH HHS [R01 AI091977, F32 AI098383] Funding Source: Medline
Ask authors/readers for more resources
Interferon-beta (IFN-beta) is widely used to treat multiple sclerosis (MS), but its mechanism of protection remains obscure. A new study shows that IFN-beta induces FoxA1(+) regulatory T cells, a new regulatory T cell population, which suppress conventional T cells via programmed cell death 1 ligand 1. This cell subset limits disease in a mouse model of MS and was found in patients with MS who responded to IFN-beta therapy (pages 272-282).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
